Downregulation of serum exosomal miR-216b predicts unfavorable prognosis in patients with non-small cell lung cancer
Authors:
- 30 December 2019
- journal article
- research article
- Published by SAGE Publications in Cancer Biomarkers
- Vol. 27 (1) , 113-120
Abstract
BACKGROUND: Increasing evidence have shown that miRNAs play an important role in the development and progression of non-small cell lung cancer (NSCLC). OBJECTIVE: In this study, we aimed to analyze serum exosomal miR-216b expression in NSCLC patientsKeywords
This publication has 23 references indexed in Scilit:
- Lung cancer and metastasis: new opportunities and challengesCancer and Metastasis Reviews, 2015
- Exosomes: A Role for Naturally Occurring Nanovesicles in Cancer Growth, Diagnosis and TreatmentCurrent Gene Therapy, 2015
- MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HBx-miR-216b-IGF2BP2 signaling pathwayCell Death & Disease, 2015
- Human leukocyte antigen (HLA)‐G gene polymorphism in patients with non‐small cell lung cancerThoracic Cancer, 2015
- Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathwayOncotarget, 2015
- miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinomaJournal of Cell Science, 2011
- MicroRNA: Biogenesis, Function and Role in CancerCurrent Genomics, 2010
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- Lung Cancer ScreeningNew England Journal of Medicine, 2005
- Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implicationsEuropean Journal Of Cancer Prevention, 2001